戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 um tolerated dose of CPI-613 (as assessed by dose-limiting toxicities).
2 hrombocytopenia that required transfusion, a dose-limiting toxicity.
3 atients received pomalidomide 2 mg/d with no dose-limiting toxicity.
4 with grade 2 adverse events (AEs) defined as dose-limiting toxicity.
5 le cerebellar toxicity, thereby defining the dose-limiting toxicity.
6 aximum of 30 mg per week, until remission or dose-limiting toxicity.
7 the timing of therapeutic interventions, and dose-limiting toxicity.
8                       No patient experienced dose-limiting toxicity.
9 T-cell infusions were well tolerated with no dose-limiting toxicity.
10 ntered the phase 1 study; none experienced a dose-limiting toxicity.
11 thrombocytopenia, which has proven to be the dose-limiting toxicity.
12 ng for the mechanistic basis of efficacy and dose-limiting toxicity.
13 tion was well tolerated, without evidence of dose-limiting toxicity.
14                          Phase I revealed no dose-limiting toxicity.
15 le in blood, has rapid clearance, and causes dose-limiting toxicity.
16 h one of six or fewer patients experienced a dose-limiting toxicity.
17 rently limited by severe adverse effects and dose-limiting toxicity.
18  higher dose of 1000 mg/m(2), and both had a dose-limiting toxicity.
19     Vaccinations at all DL were safe with no dose-limiting toxicities.
20  was maintained throughout treatment with no dose-limiting toxicities.
21       The primary end point was incidence of dose-limiting toxicities.
22  mg/kg MP0250 once every 2 weeks experienced dose-limiting toxicities.
23  microg was tested without the appearance of dose-limiting toxicities.
24             Five (7%) patients in part B had dose-limiting toxicities.
25     Thrombocytopenia and leukopenia were the dose-limiting toxicities.
26 ted to a maximum of 0.24 mg/kg/d without any dose-limiting toxicities.
27 ersus-host disease (GVHD), neurotoxicity, or dose-limiting toxicities.
28 ation was escalated to 215 MBq/L without any dose-limiting toxicities.
29 sment of maximum-tolerated dose, safety, and dose-limiting toxicities.
30 olerated dose was not reached; there were no dose-limiting toxicities.
31                   Three patients experienced dose-limiting toxicities: 1 at 4.0 mg and 2 at 5.5 mg; t
32                                   Because of dose-limiting toxicities, a de-escalation cohort (10 mg
33                            In the absence of dose-limiting toxicity, a dose of 2.5 x 10(6) cells per
34 ive patients were treated; seven experienced dose-limiting toxicities (all hematologic).
35 atients in cohort 1 and four in cohort 3 had dose-limiting toxicities; all other patients were treate
36                              Patients in the dose-limiting toxicity analysis set were assessed for th
37 miting toxicities, which was analysed in the dose-limiting toxicity analysis set, which included all
38             18 patients were analysed in the dose-limiting toxicity analysis set: three at dose level
39 ptimal efficacy of standard therapies due to dose limiting toxicities and obesity-related complicatio
40 py, but later elicit minimal response due to dose-limiting toxicities and acquired resistance.
41  glands as well as to the kidney, leading to dose-limiting toxicities and adverse events affecting qu
42 mination of maximum tolerated dose including dose-limiting toxicities and determination of recommende
43 nd tolerability, including the occurrence of dose-limiting toxicities and determination of the maximu
44  remarkably improved MM patient outcome, but dose-limiting toxicities and development of resistance l
45         There were no dose de-escalations or dose-limiting toxicities and nivolumab 3 mg/kg was confi
46 ell tolerated with low systemic exposure, no dose-limiting toxicities and no immunogenicity.
47                                           No dose-limiting toxicities and no individual dose reductio
48 ly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistan
49 eir cytotoxin delivery to tumor with reduced dose-limiting toxicities and thus have the potential for
50                          Radiotherapy causes dose-limiting toxicity and long-term complications in ra
51 y of TPCS2a; other co-primary endpoints were dose-limiting toxicity and maximum tolerated dose.
52 t of the phase 1b study was the incidence of dose-limiting toxicity and recommended phase 2 dose; how
53                   A possible way to minimize dose-limiting toxicity and to optimize this treatment me
54 e available small molecule drugs suffer from dose-limiting toxicity and undesirable side effects.
55 nia due to BCL-x(l) inhibition was the major dose-limiting toxicity and was dose-related.
56 ressure [IOP] elevation, cataract, and other dose-limiting toxicities) and postoperative TT incidence
57 med to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-35
58           The primary endpoints were safety, dose-limiting toxicities, and the maximum tolerated dose
59       Primary endpoints were adverse events, dose-limiting toxicities, and the objective response rat
60 et were assessed for the primary endpoint of dose-limiting toxicity, and all patients enrolled in the
61 , difficulty in purification to homogeneity, dose-limiting toxicity, and chemical instability.
62  to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of re
63  out of six patients had a treatment-related dose-limiting toxicity, and the safety and toxicity prof
64 ral compounds may be ineffective and/or pose dose-limiting toxicity, and therefore, immune-based ther
65                          Drug resistance and dose-limiting toxicities are significant barriers for tr
66 st one dose of rilotumumab and completed the dose-limiting toxicity assessment window (first cycle of
67                                       Due to dose-limiting toxicities associated with inhibition of w
68      Primary endpoints were determination of dose-limiting toxicities at the maximum administered dos
69                      One patient experienced dose-limiting toxicity at 4 mg; the MTD was determined a
70 t least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully
71 i-cancer small molecule drugs as well as the dose-limiting toxicity caused by the nonselective action
72                                        Thus, dose-limiting toxicities commonly associated with these
73                                 However, the dose limiting toxicity delays diarrhea that is thought t
74                                              Dose limiting toxicity (DLT) is grade 4 thrombocytopenia
75 termine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of irinotecan administered
76  determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of
77 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose
78                                              Dose-limiting toxicity (DLT) assessment occurred during
79                                              Dose-limiting toxicity (DLT) consisted of worsening neur
80    Study characteristics, design parameters, dose-limiting toxicity (DLT) definition, DLT rate, patie
81                 Tumor lysis syndrome was the dose-limiting toxicity (DLT) for CLL, the maximum-tolera
82 of 6 patients treated at 1 mg/kg experienced dose-limiting toxicity (DLT) from immune-related adverse
83 ses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irrespective of
84                     The primary endpoint was dose-limiting toxicity (DLT) in the first treatment cycl
85 % escalations in three patient cohorts until dose-limiting toxicity (DLT) occurred.
86 dentify the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan in patients w
87 rases that met protocol-defined criteria for dose-limiting toxicity (DLT) or temporarily holding ther
88 reated every 2 weeks x 4 doses with a 4-week dose-limiting toxicity (DLT) period.
89                                              Dose-limiting toxicity (DLT) was defined as any treatmen
90                                              Dose-limiting toxicity (DLT) was defined as grade 3 or w
91                                           No dose-limiting toxicity (DLT) was encountered on dose lev
92                                              Dose-limiting toxicity (DLT) was failure to reconstitute
93  48 mg/m(2)/d and continued until consistent dose-limiting toxicity (DLT) was observed.
94                     The primary endpoint was dose-limiting toxicity (DLT), assessed during the first
95 a was the most common drug-related (93%) and dose-limiting toxicity (DLT), constituting four of 10 DL
96 toxicity, and 34 patients were evaluable for dose-limiting toxicity (DLT).
97               Primary outcome was safety and dose-limiting toxicity (DLT).
98  increased by 20 mg/m(2)/d in the absence of dose-limiting toxicity (DLT).
99 ts included maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
100                                              Dose-limiting toxicities (DLTs) in the MONO study were f
101                                              Dose-limiting toxicities (DLTs) were assessed during cyc
102                                              Dose-limiting toxicities (DLTs) were assessed during the
103                        Using a 3 + 3 design, dose-limiting toxicities (DLTs) were assessed weekly dur
104                                              Dose-limiting toxicities (DLTs) were evaluated during th
105                                              Dose-limiting toxicities (DLTs) were grade 3 hypersensit
106                                           No dose-limiting toxicities (DLTs) were observed at the 50,
107 ermine maximum-tolerated dose (MTD), safety, dose-limiting toxicities (DLTs), and pharmacokinetics (P
108 te plus romidepsin designed to determine the dose-limiting toxicities (DLTs), maximum tolerated dose,
109                                      Safety, dose-limiting toxicities (DLTs), maximum-tolerated dose
110 ade 3 hand-foot skin reaction and/or rash as dose-limiting toxicities (DLTs).
111            Initially, six patients developed dose-limiting toxicities (DLTs): grade (G) 2 nausea at 1
112                                          Two dose-limiting toxicities (DLTs; grade 3 arthralgia and g
113 men was identified based on the incidence of dose-limiting toxicities (DLTs; primary endpoint): 400 m
114                                  We assessed dose limiting toxicity during the first 45 days after in
115                     The primary endpoint was dose-limiting toxicities during cycle 1 according to inv
116 dverse events in both phase 1a and 1b and as dose-limiting toxicities during phase 1a.
117   The primary endpoint was the occurrence of dose-limiting toxicities during the first 2 weeks of tre
118 ion algorithm and depending on the number of dose-limiting toxicities during the first 3-week assessm
119 bjectives were to determine the incidence of dose-limiting toxicities during the first cycle of CMP t
120               The primary safety outcome was dose-limiting toxicity effects.
121                                          One dose-limiting toxicity event (grade 3 abdominal pain) oc
122 % of scheduled pamiparib doses, or who had a dose-limiting toxicity event during cycle 1.
123                                There were no dose-limiting toxicity events in either group.
124                         No cataract or other dose-limiting toxicity events occurred.
125                                              Dose-limiting toxicities for cisplatin administration, i
126 ry endpoints were maximum tolerated dose and dose-limiting toxicity for phase 1, and the proportion o
127                            Hypertension is a dose-limiting toxicity for VEGF inhibitors.
128 T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibi
129 xamined because of recurrent grade 2 and non-dose-limiting toxicity grade 3 and 4 adverse events (AEs
130                  At 600 mg, two patients had dose-limiting toxicities (grade 2 hypertension, dermatit
131                                          Two dose-limiting toxicities (grade 2 pulmonary embolism and
132 in the 450 mg dose-escalation cohort had two dose-limiting toxicities (grade 3 diarrhoea and grade 3
133                                          Two dose-limiting toxicities (grade 3 rash; grade 4 thromboc
134                              There were four dose-limiting toxicities (grade 4 neutropenia) at 5 mg p
135                                              Dose-limiting toxicity (grade 3 anorexia) occurred in on
136                                          One dose-limiting toxicity (grade 3 hyperbilirubinaemia) was
137 icities; one patient treated at the RP2D had dose-limiting toxicity (grade 3 sepsis).
138                                              Dose-limiting toxicity (grade 3/4 diarrhea) occurred at
139               Only one patient experienced a dose-limiting toxicity-grade 3 transient asymptomatic hy
140  eight patients, four experienced unexpected dose-limiting toxicities: grade 4 sepsis syndrome, grade
141                     Two patients experienced dose-limiting toxicity: grade 3 conjunctivitis and trans
142                  Eight of nine patients with dose-limiting toxicity had grade 4 thrombocytopenia.
143 ed clinical activity in cancer patients, but dose-limiting toxicities have hindered its incorporation
144 tient number 2; anaemia and lymphopenia were dose-limiting toxicities); hyperglycaemia (in patient nu
145                                          One dose-limiting toxicity (ie, grade 3 thrombocytopenia) oc
146  which expanded to six patients because of a dose-limiting toxicity (ie, junctional cardiac rhythm).
147 al application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 10
148 ase 1b primary endpoint was the incidence of dose-limiting toxicities in all phase 1b patients who re
149 nd related infections are the most important dose-limiting toxicities in anticancer chemotherapy and
150                            Four patients had dose-limiting toxicities in cycle 1 (phase I).
151 125 mg daily, was determined on the basis of dose-limiting toxicities in four patients (100 mg, grade
152 erglycemia and grade 4 hypophosphatemia were dose-limiting toxicities in one patient treated at 1.0 m
153               During phase 1b, there were no dose-limiting toxicities in the dose cohorts tested.
154 table safety and tolerability; there were no dose-limiting toxicities in the dose-escalation phase.
155                                              Dose-limiting toxicities in two patients at 70 mg/m(2) w
156                                              Dose-limiting toxicity in cycle 1 was grade 3 diarrhea i
157 mplement activation and associated pain, the dose-limiting toxicity in neuroblastoma immunotherapy.
158 acy of PI3Kalpha inhibitors while mitigating dose-limiting toxicity in patients with head and neck sq
159                  Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide
160                                              Dose-limiting toxicity in the phase 1 portion was neutro
161                           Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acu
162 Cytokine release syndrome (CRS) was the only dose-limiting toxicity (in three [6%] of 53 patients) an
163                                              Dose-limiting toxicities included diarrhea and neutropen
164                                              Dose-limiting toxicities included grade 3 bilateral reti
165                                              Dose-limiting toxicities included grade 3 fatigue (200 m
166                                              Dose-limiting toxicities included grade 4 thrombocytopen
167                                      Grade 3 dose-limiting toxicities included headache, nausea/vomit
168                                          Non-dose-limiting toxicities included left ventricular dysfu
169                                         Five dose-limiting toxicities, including fatigue (n = 2), thr
170                                              Dose-limiting toxicities, including grade 3 type 2 diabe
171                     Nine (6%) patients had a dose-limiting toxicity, including one patient who died f
172                            Four patients had dose-limiting toxicities (intractable grade 2 nausea [n=
173 cation to FGF19-driven HCC may be limited by dose-limiting toxicities mediated by FGFR1-3 receptors.
174           Eight patients (24%) experienced a dose-limiting toxicity, most commonly anorexia, nausea,
175  injections, with no serious adverse events, dose-limiting toxicities, nor evidence for anti-VRC01 an
176       The first 21-day treatment cycle was a dose-limiting toxicity observation period (phase 1a; saf
177  enrolled and 12 were evaluable for toxicity Dose limiting toxicity observed included grade 3 hyperbi
178                                              Dose-limiting toxicities observed during dose escalation
179                                              Dose-limiting toxicities observed in patients receiving
180 l (GI) syndrome is a serious side effect and dose-limiting toxicity observed in patients undergoing l
181                                    The major dose-limiting toxicity observed was hemolysis, indicatin
182                                No additional dose-limiting toxicities occurred and the decision was m
183                                          Two dose-limiting toxicities occurred at the 17 Gy dose leve
184             No deaths related to toxicity or dose-limiting toxicities occurred during induction.
185                                           No dose-limiting toxicities occurred during the first 6 wee
186                                           No dose-limiting toxicities occurred, and a maximum-tolerat
187                                           No dose-limiting toxicities occurred, and no new safety sig
188                                           No dose-limiting toxicities occurred.
189                   No infusional reactions or dose-limiting toxicities occurred.
190        All were treated with 5 mg because no dose-limiting toxicities occurred.
191        No deaths, serious adverse events, or dose-limiting toxicities occurred.
192 rates of clinically significant pneumonitis, dose-limiting toxicity occurred and was dominated by lat
193                                          One dose-limiting toxicity occurred at 200 mg (the patient d
194                                              Dose-limiting toxicity occurred at level 6 (30-mg/m(2) b
195                                     Only one dose-limiting toxicity occurred, at the 20 mg/kg dose, a
196 ation schedule was applied until moderate or dose-limiting toxicity occurred, followed by a 3+3 desig
197         The primary endpoint was the rate of dose- limiting toxicities occurring within 4 weeks of in
198  to determine the maximum tolerated dose and dose limiting toxicities of brentuximab vedotin combined
199 ition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.
200  to establish the maximum tolerated dose and dose-limiting toxicity of bevacizumab when administered
201 low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib.
202                Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effe
203 oses can improve activity while reducing the dose-limiting toxicity of conventional dosing schedules.
204 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obse
205 umulative sensory neurotoxicity (sNT) is the dose-limiting toxicity of oxaliplatin, which commonly le
206  time can temporally segregate efficacy from dose-limiting toxicity of streptozocin, a chemotherapeut
207                                       Due to dose-limiting toxicity of the small molecule payload, an
208 /kg, with two (30%) of six patients having a dose-limiting toxicity (one grade 3 increased aspartate
209          Transient grade 3 hypophosphatemia (dose-limiting toxicity, one patient) and grade 3 pruritu
210         Across all doses, three patients had dose-limiting toxicities; one patient treated at the RP2
211                       There were no reported dose-limiting toxicities or evidence of cumulative toxic
212            MABp1 was well tolerated, with no dose-limiting toxicities or immunogenicity.
213 ell tolerated with no transfusion reactions, dose-limiting toxicities or macrophage activation syndro
214                                           No dose-limiting toxicities or relevant safety events were
215 across the dosing cycle was achieved without dose-limiting toxicity or maximally tolerated dose.
216 sored at the time of analysis as a result of dose-limiting toxicity or other reasons.
217 iscontinuations because of drug-related AEs, dose-limiting toxicities, or antidrug antibodies were re
218 tumumab 15 mg/kg, only two of whom had three dose-limiting toxicities: palmar-plantar erythrodysesthe
219 herapy, where high doses are required, their dose limiting toxicities preclude success.
220              One patient (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus).
221 , to deliver a potent immunosuppressant with dose-limiting toxicity, rapamycin (Rapa) also known as S
222 omas, ivosidenib was well tolerated, with no dose-limiting toxicities reported.
223 one was generally well tolerated with only 1 dose-limiting toxicity reported (grade 3 pneumonia at 20
224   Two patients in cohort 2 developed grade 3 dose-limiting toxicity (seizures, renal insufficiency).
225                        Primary outcomes were dose-limiting toxicities, the maximum tolerated dose of
226 x given everolimus on days 1-14) without any dose-limiting toxicities; therefore, everolimus 10 mg/da
227 lling 6 study design with de-escalation upon dose-limiting toxicities to establish the recommended ph
228                               We observed no dose-limiting toxicity, treatment-induced immunosuppress
229              In the dose-escalation part, no dose limiting toxicity was reported and the trial's safe
230 The maximum-tolerated dose was 680 mg/d, and dose-limiting toxicity was a reversible and asymptomatic
231  that ABDNAZ was not myelosuppressive and no dose-limiting toxicity was apparent following daily admi
232                                              Dose-limiting toxicity was defined as a grade 3 or great
233 ximum-tolerated dose was 200 mg/day, and the dose-limiting toxicity was grade 3 QT prolongation.
234                                          The dose-limiting toxicity was grade 3 rash.
235 ong-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy.
236                                              Dose-limiting toxicity was not observed.
237  (n = 1), were observed with schedule A; one dose-limiting toxicity was observed (elevated AST/ALT) w
238                                           No dose-limiting toxicity was observed and the maximum tole
239                                           No dose-limiting toxicity was observed at any dose.
240             Of 15 subjects treated on study, dose-limiting toxicity was observed at both dose levels
241 s with heavily pretreated ovarian cancer; no dose-limiting toxicity was observed in 16 patients treat
242 grade 3 or 4 toxicity event was reported, no dose-limiting toxicity was observed in 47 trials (57%).
243                                  Notably, no dose-limiting toxicity was observed in a Phase I clinica
244                                           No dose-limiting toxicity was observed in phase I once ever
245           Idasanutlin was well tolerated; no dose-limiting toxicity was observed, but low-grade gastr
246                                           No dose-limiting toxicity was observed.
247 travenous decitabine in the cohort and if no dose-limiting toxicity was observed.
248  in either the CLL or NHL cohort, and only 1 dose-limiting toxicity was observed.
249                                           No dose-limiting toxicity was recorded with durvalumab plus
250                                          One dose-limiting toxicity was reported (grade 3 hyponatremi
251                                          One dose-limiting toxicity was reported in the 1.0 mg/kg coh
252                                           No dose-limiting toxicity was reported, and only three pati
253                               A total of six dose limiting toxicities were reported in four patients,
254 as used to determine maximum tolerated dose; dose-limiting toxicities were assessed during cycle 1.
255                                              Dose-limiting toxicities were assessed during the first
256 tuzumab deruxtecan from 0.8 to 8.0 mg/kg and dose-limiting toxicities were assessed over a 21-day cyc
257                                           No dose-limiting toxicities were encountered.
258                 MABp1 was well tolerated, no dose-limiting toxicities were experienced in this study,
259                                              Dose-limiting toxicities were grade 2 mood alteration (8
260                                              Dose-limiting toxicities were grade 3 nausea, vomiting,
261                                              Dose-limiting toxicities were grade 3 palmar plantar ery
262                                              Dose-limiting toxicities were hepatic and renal.
263                                           No dose-limiting toxicities were identified, and maximum to
264                                          Two dose-limiting toxicities were noted in patients with mye
265                                           No dose-limiting toxicities were noted in the dose-escalati
266                                           No dose-limiting toxicities were noted.
267                                           No dose-limiting toxicities were observed and ocular advers
268                                           No dose-limiting toxicities were observed and the maximum-t
269                                           No dose-limiting toxicities were observed at doses of 30-40
270                                           No dose-limiting toxicities were observed during cycle 1 of
271                                           No dose-limiting toxicities were observed in the first thre
272                                           No dose-limiting toxicities were observed in the phase I po
273                                              Dose-limiting toxicities were observed in three (11%) of
274                  In part 1 (13 patients), no dose-limiting toxicities were observed, and 16 mg/kg was
275                                           No dose-limiting toxicities were observed, therefore, a max
276 ccurred before CAR-NKT cell infusion, and no dose-limiting toxicities were observed.
277                                           No dose-limiting toxicities were observed.
278 dose until we were able to establish that no dose-limiting toxicities were observed.
279                                              Dose-limiting toxicities were rectal ulceration and prot
280                                           No dose-limiting toxicities were reported and maximum toler
281                                           No dose-limiting toxicities were reported and the maximum t
282                                              Dose-limiting toxicities were reported in 3/14 patients
283                                           No dose-limiting toxicities were reported in phase 1, and p
284                                              Dose-limiting toxicities were reported in two of three p
285                 Although no protocol-defined dose-limiting toxicities were reported, a high incidence
286                                           No dose-limiting toxicities were reported.
287                                   Results No dose-limiting toxicities were reported; nine of 38 repor
288                                          The dose-limiting toxicities were reversible severe blurred
289                                              Dose-limiting toxicities were sepsis and neutropenia.
290            Serious AEs, sepsis episodes, and dose-limiting toxicities were similar between treatment
291                                              Dose-limiting toxicities were supraventricular tachyarrh
292                         Pharmacokinetics and dose-limiting toxicities were used to establish the reco
293 ed during cycle 1 due to an adverse event or dose-limiting toxicity were included in the evaluation o
294                    Prespecified criteria for dose-limiting toxicity were not met.
295           Human clinical trials indicated no dose-limiting toxicity when administered at doses up to
296 odels, have failed in clinical trials due to dose-limiting toxicity when administered systemically.
297 rib, with the exception of the occurrence of dose-limiting toxicities, which was analysed in the dose
298                              We observed two dose-limiting toxicities with ricolinostat 160 mg twice
299                         Constipation was the dose-limiting toxicity with both routes.
300 ssessment method on the basis of the rate of dose-limiting toxicities within the first 15 weeks of th

 
Page Top